184970-32-9

Usage

Uses

Used in Pharmaceutical Industry:
1-Pyrrolidin-3-yl-piperidine is used as a chemical precursor for the synthesis of various pharmaceuticals, playing a crucial role in the development of new drugs. Its unique structure allows it to be a building block in the creation of medicinal compounds that can address a range of health conditions.
Used in Controlled Substances Regulation:
1-Pyrrolidin-3-yl-piperidine is used as a controlled substance in jurisdictions like the United States to prevent its misuse in the production of illicit drugs. As a Schedule II controlled substance, it is subject to strict regulations to mitigate the risk of abuse and addiction.

InChI:InChI=1/C9H18N2/c1-2-6-11(7-3-1)9-4-5-10-8-9/h9-10H,1-8H2

Upstream product

• 18471-40-4 1-Benzyl-3-aminopyrrolidine 
• 690265-35-1 (3R)-1-(1-benzyl-pyrrolidin-3-yl)-piperidine 
• 110-89-4 piperidine 

Downstream Products

• 690265-36-2 1-[1-(4-bromo-phenyl)-pyrrolidin-3-yl]-piperidin 
• 1608129-58-3 3-piperidin-1-yl-pyrrolidine-1-carboxylic acid [5-(4-methoxyphenyl)-2H-pyrazol-3-yl]amide 
• 1608129-59-4 3-piperidin-1-yl-pyrrolidine-1-carboxylic acid [5-(2-difluoromethoxyphenyl)-2H-pyrazol-3-yl]amide 

Relevant academic research and scientific papers

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors

The present invention relates to certain 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives that inhibit kinases, in particular VEGFR and/or PDGFR kinases. Pharmaceutical compositions comprising these compounds, methods of treating diseases mediated by kinases utilizing pharmaceutical compositions comprising these compounds, and methods of preparing them are also disclosed.